Compare Amgen, Inc. (AMGN) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Vital Farms Inc — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Vital Farms Inc trades at $12.66 (market cap $554.89M). The key difference: Amgen, Inc. is far larger — about 353.4× Vital Farms Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals.
| AMGN | VITL | |
|---|---|---|
Market Cap | $196.12B | $554.89M |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $52.41 |
52-Week Low | $271.18 | $8.28 |
Enterprise Value | $241.41B | $557.69M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Vital Farms (VITL) trades at $12.95, down 0.08% on the day, with a bullish technical signal supported by moving averages but overbought RSI readings. The stock shows solid profitability with a 6.1% net margin and 15.44% ROE, though earnings missed expectations in two recent quarters. Valuation appears reasonable with a P/E of 12.45 and P/S of 0.75. Recent news highlights volatility, including a class-action lawsuit filed in May 2026, while cash flow trends indicate significant investing outflows.
The outlook is mixed: analyst consensus leans bullish with a $13.50 price target, but risks include legal overhangs, earnings volatility, and negative cash flow. Revenue growth is modest, projected at $784M for 2026, but profit margins are declining. Investors should weigh strong fundamentals against near-term headwinds from litigation and operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
